The right drugs for the right patient.
Selecting patients who have the susceptibility biomarker (or drug target) and who don’t have the resistance biomarker ensures that patients most likely to respond to treatment will be included in the trial.
All cancer patients deserve superior therapy.
ResCu can help identify patients that have the target and would have a suboptimal response due to treatment resistance. These non-responsive patients have biological nuances that can lead to new resistance targets and therapeutics that result in potentially superior clinical outcomes.
Precision resistance target discovery.
Each biological insight separating superior and suboptimal responders is a potential new druggable target and therapeutic advancement.